Business Wire

OR-LATTICE-SEMICONDUCTOR

25.8.2021 22:02:13 CEST | Business Wire | Press release

Share
Lattice Certus-NX FPGAs Optimized for Automotive Applications

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today expanded its growing portfolio of automotive products with the announcement of versions of the Lattice Certus™-NX FPGA family optimized for infotainment, advanced driver assistance systems (ADAS), and safety-focused applications. Built on the Lattice Nexus™ platform, these new Certus-NX devices combine automotive-grade features with best-in-class I/O density, power efficiency, small size, reliability, instant-on performance, and support for fast PCI Express (PCIe) and Gigabit Ethernet interfaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005002/en/

“Demand for automotive semiconductors is increasing as the ongoing trends towards automotive system electrification, autonomy, and connectivity have manufacturers looking for ways to deliver the advanced features and user experiences drivers are looking for in their next vehicle,” said Jay Aggarwal, Director of Silicon Product Marketing, Lattice Semiconductor. “With class-leading performance and power efficiency, support for popular I/O standards in a small form factor, and high reliability, our Certus-NX general purpose FPGAs make a compelling silicon platform for the next-generation automotive applications car makers are eager to provide to their customers.”

“As more automotive systems go digital, modern cars have essentially become mobile datacenters. Automotive developers need access to secure and reliable silicon solutions with fast I/O performance to ensure mission-critical automotive systems can perform their functions instantaneously,” said K. Ganesh Rao, Practice Head – FPGA Solutions, Tata Elxsi. “Lattice Certus-NX FPGAs provide the reliability, performance, and feature set we need to make tomorrow’s automotive applications possible.”

The latest Certus-NX FPGAs are ideal for automotive applications like motor control, LED control in in-vehicle infotainment (IVI) systems, in-vehicle networking (IVN), and sensor data co-processing in ADAS applications. Key features of Certus-NX FPGAs include:

  • Low power consumption – Up to 4X lower power use than similar FPGAs, with a programmable back bias that enables user-selectable high performance or low power operating modes, depending on the needs of the application.
  • Small form factor – Up to 3X smaller with up to 2X the I/O density per mm2 in comparison to similar competing FPGAs.
  • Instant-on performance – Ultra-fast device configuration from SPI memory up to 12X faster than similar competing FPGAs, with individual I/O able to configure in just 3 ms, and full-device startup in only 8-14 ms, depending on device capacity.
  • Robust I/O interfacing capability – Lattice’s extensive Certus-NX I/O IP library includes:
    • 1.5 Gbps differential I/O with performance up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3.
  • Automotive certification and high reliability – Certus-NX FPGAs are AEC-Q100 qualified and provide up to 100X better soft error rate (SER) performance than similar FPGAs.
  • Authentication and encryption – To protect bitstreams against unauthorized access, Certus-NX FPGAs support AES-256 encryption with ECDSA; they are currently the smallest FPGAs on the market to support ECDSA.
  • Ease of use/design – Lattice Radiant® and Lattice Propel™ software tools help simplify and accelerate automotive system design. Certus-NX FPGAs are also supported by the Lattice mVision™ and Lattice sensAI™ solution stacks so designers can leverage the stacks’ modular hardware platforms, reference designs, neural network IP cores, and custom design services to accelerate automotive vision system design.

Automotive-grade versions of Certus-NX FPGAs are now sampling with select customers. For more information about the Lattice technologies mentioned above, please visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye